Vanderbilt University Medical Center: Molecular Profiles of Tissue Plus Circulating Tumor DNA Can Better Guide Cancer Care
January 23, 2024
January 23, 2024
NASHVILLE, Tennessee, Jan. 23 (TNSres) -- Vanderbilt University Medical Center issued the following news:
The current standard of care for identifying targetable mutations in cancer treatment is to conduct molecular profiles on tumor tissue samples, but a study published Monday in JAMA Network Open indicates that adding liquid biopsy testing for circulating tumor DNA mutations increases targetable mutation detection rates.
For example, in patients with breast cancer, fr . . .
The current standard of care for identifying targetable mutations in cancer treatment is to conduct molecular profiles on tumor tissue samples, but a study published Monday in JAMA Network Open indicates that adding liquid biopsy testing for circulating tumor DNA mutations increases targetable mutation detection rates.
For example, in patients with breast cancer, fr . . .